Diabetes drug maker Amylin Pharmaceuticals Inc. (AMLN) drew four first-round bids valuing the company at $25 to $29 a share, with Pfizer Inc. (PFE) dropping out of the process, Bloomberg News reported Monday on its website, citing people with knowledge of the process.
AstraZeneca Plc (AZN), Sanofi (SNY), Merck & Co. (MRK) and Bristol-Myers Squibb Co. (BMY) submitted offers, with revised offers due by the end of the month and a sale likely in July, two people told Bloomberg.
Representatives for Amylin, Merck, Bristol-Myers, AstraZeneca, Sanofi and Pfizer declined comment to Bloomberg.
Full story at: www.bloomberg.com/news/2012-06-04/amylin-said-to-draw-bids-of-25-to-29-a-share-in-first-round.html
-Dow Jones Newswires; 212-416-2900